Previous 10 | Next 10 |
BioMarin is a leader in rare disease therapy discovery with multiple competitive advantages including scale, expertise, patents and relationships. Two major catalysts for 2021 provide investors with favorable risk/reward skew afforded by a low share price that should not be ignored. ...
BMEZ is a fund that is focused on the healthcare space, more specifically, a focus on the health sciences industry. They overlay this healthcare strategy with an option writing strategy to potentially enhance income. The fund has done exceptionally well since its launch right befo...
The following slide deck was published by Genmab A/S in conjunction with their 2020 Q3 earnings call. For further details see: Genmab A/S 2020 Q3 - Results - Earnings Call Presentation
Genmab A/S (GMAB) announces the initiation of a 480-subject Phase 3 clinical trial comparing bispecific antibody (simultaneously binds to CD3 and CD20) epcoritamab to chemo in patients with diffuse large B-cell lymphoma ((DLBCL)). The primary endpoint is overall survival.The company is co-dev...
Image source: The Motley Fool. Genmab A/S (NASDAQ: GMAB) Q3 2020 Earnings Call Nov 4, 2020 , 12:00 p.m. ET Operator Continue reading For further details see: Genmab A/S (GMAB) Q3 2020 Earnings Call Transcript
Genmab A/S (GMAB) Q3 2020 Earnings Conference Call November 4, 2020 12:00 ET Company Participants Jan van de Winkel - President and Chief Executive Officer Anthony Pagano - Chief Financial Officer Judith Klimovsky - Chief Development Officer Anthony Mancini - Chief Operating Officer Conferenc...
Genmab A/S (GMAB): Q3 GAAP EPS of DKK8.04 beats by $DKK1.88.Revenue of DKK1.72B (+65.4% Y/Y) beats by DKK260M.Press Release For further details see: Genmab A/S EPS beats by DKK1.88, beats on revenue
The first participant has been dosed in an additional arm of a Phase 1b clinical trial evaluating ADC Therapeutics' (ADCT) antibody-drug conjugate camidanlumab tesirine (Cami) (formerly ADCT-301), combined with Merck's (MRK) Keytruda (pembrolizumab), in patients with advanced solid ...
Genmab A/S (GMAB) and ADC Therapeutics SA (ADCT) have amended their 2013 collaboration agreement related to continued development and commercialization of antibody-drug conjugate ((ADC)) camidanlumab tesirine (Cami).The revised contract eliminates the defined divestment process and allows ADC...
Aging population, lifestyle changes and pandemics have created a huge demand for patient-focused healthcare. Biotech stocks like Seagen (SGEN), Genmab A/S (GMAB), Amedisys (AMED), and Masimo (MASI) could dominate the industry based on their disruptive technology, unique offerings and tremendo...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...
2024-06-27 09:00:08 ET Kaveri Pohlman from BTIG issued a price target of $47.00 for GMAB on 2024-06-27 07:34:00. The adjusted price target was set to $47.00. At the time of the announcement, GMAB was trading at $25.67. The overall price target consensus is at $41.80 with...